Regeneron Pharmaceuticals Inc (REGN) is a publicly traded biotechnology business based in the US. In the week up to 8 August Regeneron Pharmaceuticals shares surged 9.36% to a closing position of $630.63. Over the last 12 months, Regeneron Pharmaceuticals's share price has risen by 2.54% from $608.45. Regeneron Pharmaceuticals is listed on the NASDAQ and employs 10,368 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
US shares
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £12.79 £2,571.09 total |
Capital at risk |
|
£0 | £250 | £21.03 £2,579.34 total |
Capital at risk |
 |
£0 | £1 | £11.51 £2,569.81 total |
Capital at risk |
|
£0 | No minimum | £25.58 £2,583.88 total |
Capital at risk |
 |
£0 | £1 | £37.53 £2,595.83 total |
Capital at risk |
 |
£0 | £0.01 | £2.56 £2,560.86 total |
Capital at risk |
 |
£9.99 per month | No minimum | £46.36 £2,604.67 total |
Capital at risk |
 |
£0 | £50 | £12.79 £2,571.09 total |
Capital at risk |
 |
£36 per year | £20 | £41.48 £2,599.78 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of $623.9
| 1 week (2022-08-05) | 1.68% |
|---|---|
| 1 month (2022-07-12) | 2.26% |
| 3 months (2022-05-11) | 1.77% |
| 6 months (2022-02-09) | 0.67% |
| 1 year (2021-08-12) | 2.62% |
|---|---|
| 2 years (2020-08-12) | 1.89% |
| 3 years (2019-08-12) | 110.87% |
| 5 years (2017-08-11) | 33.71% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Regeneron Pharmaceuticals shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.2981. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $7.4 billion (£6 billion).
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals's total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Regeneron Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.33 |
|---|---|
| Total ESG percentile | 26.82 |
| Environmental score | 1.51 |
| Environmental score percentile | 2 |
| Social score | 13.94 |
| Social score percentile | 2 |
| Governance score | 5.88 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
| Open | $638.63 |
|---|---|
| High | $643.98 |
| Low | $622.3688 |
| Close | $623.9 |
| Previous close | $641.49 |
| Change | $-17.59 |
| Change % | -2.7421% |
| Volume | 452,864 |
| 52-week range | $538.01 - $747.42 |
|---|---|
| 50-day moving average | $602.432 |
| 200-day moving average | $633.1092 |
| Wall St. target price | $684.36 |
| PE ratio | 12.6454 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $49.86 |
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $538.01 up to $747.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2843. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
